Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Tracking # 20-1089304
What you'll learn
Upon completion of this activity, participants should be able to:
- Assess guideline-recommended treatment combination and sequencing strategies in NDMM
- Evaluate the role of MRD assessment in NDMM treatment
- Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM
- Discuss strategies to monitor and manage treatment-related toxicities and optimize survivorship care
Course overview
Presented by leading expert Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, this activity will explore guidance on current standards and new directions in newly diagnosed multiple myeloma.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Medical Practitioner
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
Physician and Surgeon Compact License
New Hampshire Board of Medicine
Physician
Tennessee Board of Medical Examiners
Medical Doctor
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Timothy John Feyma, MD, discloses that he has served on a speaker's bureau for Acadia Pharmaceuticals and PTC Therapeutics.
i3 Health has mitigated all relevant financial relationships.
Take it Here
- This course reports to CE Broker immediately upon completion.
- Complete all courses at your own pace online.
- Quality and enjoyable courses.
- Modern experience, accessible from any device.
- All courses affordably priced.